NORTHWEST Story

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;'>NB</div>
NWBO -- USA Stock  

USD 0.91  0.01  1.09%

NORTHWEST BIOTHERAPEUTICS PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.0161. Accounts Payable Turnover is expected to rise to 0.0217 this year, although the value of Net Income Per Employee will most likely fall to (6.2 M). The goal of this thesis is to forecast a future value of NORTHWEST BIOTHERAPEUTICS using technical analysis. What exactly are NORTHWEST BIOTHERAPEUTICS institutional investors should expect in September?
Published over a month ago
View all stories for NORTHWEST BIOTHERAPEUTICS | View All Stories
Are NORTHWEST (OTC:NWBO) institutional investors starting to hold back?
This firm has a beta of 0.7722. Let's try to break down what NORTHWEST's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NORTHWEST BIOTHERAPEUTICS will likely underperform. The beta indicator helps investors understand whether NORTHWEST BIOTHERAPEUTICS moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if NORTHWEST deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as NORTHWEST BIOTHERAPEUTICS. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for NORTHWEST BIOTHERAPEUTICS


Watch out for price decline

Please consider monitoring NORTHWEST BIOTHERAPEUTICS on a daily bases if you are holding a position in it. NORTHWEST BIOTHERAPEUTICS is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as NORTHWEST BIOTHERAPEUTICS stock to be traded above the $1 level to remain listed. If NORTHWEST BIOTHERAPEUTICS stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is NORTHWEST BIOTHERAPEUTICS's Liquidity

NORTHWEST BIOTHERAPEUTICS financial leverage refers to using borrowed capital as a funding source to finance NORTHWEST BIOTHERAPEUTICS INC ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NORTHWEST BIOTHERAPEUTICS financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NORTHWEST BIOTHERAPEUTICS's total debt and its cash.

How NORTHWEST utilizes its cash?

To perform a cash flow analysis of NORTHWEST BIOTHERAPEUTICS, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NORTHWEST BIOTHERAPEUTICS is receiving and how much cash it distributes out in a given period. The NORTHWEST BIOTHERAPEUTICS cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NORTHWEST BIOTHERAPEUTICS Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (34.37 Million)

Acquisition by Leslie Goldman of 5415952 shares of NORTHWEST BIOTHERAPEUTICS subject to Rule 16b-3

Legal trades by NORTHWEST BIOTHERAPEUTICS insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NORTHWEST insider trading alert for grant of options to purchase common stock par value $0.001 by Leslie Goldman, Senior Vice President General Counsel, on 2nd of July 2020. This event was filed by Northwest Biotherapeutics with SEC on 2020-07-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is the case for NORTHWEST BIOTHERAPEUTICS Investors

The latest price rise of NORTHWEST BIOTHERAPEUTICS INC may encourage institutional investors to take a closer look at the firm as it closed today at a share price of 0.33 on 1,469,634 in trading volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.49. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the NORTHWEST BIOTHERAPEUTICS partners.

Returns Breakdown

Return on Investment(663.52)
Return on Assets(1.5)
Return on Equity0.4
Return Capital0.65
Return on Sales(7.76)

Will NORTHWEST BIOTHERAPEUTICS growth be viable after the rise?

Jensen alpha is down to 1.03. It may entail a possible volatility slide. NORTHWEST BIOTHERAPEUTICS INC is displaying above-average volatility over the selected time horizon. Investors should scrutinize NORTHWEST BIOTHERAPEUTICS INC independently to ensure intended market timing strategies are aligned with expectations about NORTHWEST BIOTHERAPEUTICS volatility. NORTHWEST BIOTHERAPEUTICS INC is a potential penny stock. Although NORTHWEST BIOTHERAPEUTICS may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in NORTHWEST BIOTHERAPEUTICS INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

The Current Takeaway on NORTHWEST BIOTHERAPEUTICS Investment

Whereas other companies under the biotechnology industry are still a bit expensive, NORTHWEST BIOTHERAPEUTICS may offer a potential longer-term growth to institutional investors. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NORTHWEST BIOTHERAPEUTICS.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of NORTHWEST BIOTHERAPEUTICS INC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com